Scholar Rock To Present Clinical And Biomarker Data From The Phase 1 DRAGON Trial At The SITC 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock (NASDAQ:SRRK), a Phase 3 clinical-stage biopharmaceutical company, announced it will present clinical and biomarker data from the Phase 1 DRAGON trial at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The trial involves patients with advanced solid tumors treated with SRK-181, a selective latent TGFβ1 inhibitor. The company aims to establish the proof of mechanism of SRK-181, which has the potential to transform cancer immunotherapy by overcoming resistance to checkpoint inhibitor therapy.
October 19, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scholar Rock's announcement to present clinical and biomarker data from the Phase 1 DRAGON trial could potentially boost investor confidence. The trial involves SRK-181, a drug that could transform cancer immunotherapy.
The announcement of Scholar Rock presenting clinical and biomarker data from the Phase 1 DRAGON trial at a prestigious event like the SITC Annual Meeting could potentially boost investor confidence. The trial involves SRK-181, a drug that could transform cancer immunotherapy by overcoming resistance to checkpoint inhibitor therapy. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100